TOPLINE:

Men with type 2 diabetes (T2D) who initiated SGLT2 inhibitors showed nearly double the risk for phimosis after 1 year of treatment than those who initiated GLP-1 receptor agonists (GLP-1 RAs). This elevated risk persisted for over 8 years of follow-up.

METHODOLOGY:

SGLT2 inhibitors decrease hyperglycaemia by promoting glucose excretion through the kidneys, causing glucosuria, but raise concerns about an approximately threefold elevated risk for genital infections.

Researchers in Denmark emulated a target trial to compare the risk for phimosis between male metformin users with T2D who initiated SGLT2 inhibitors (n = 32,543; median age, 62.8 years) and those who initiated GLP-1 RAs (n = 14,730; median age, 63.1 years) from January 2016 to December 2021.

The primary outcome

See Full Page